Agreement with speciality chemical company, Croda International, to design and manufacture a new active skincare ingredient based on SkinBiotix™ technology and investigate specific cosmetic ingredient applications to target.
- Agreement with speciality chemical company, Croda International, to design and manufacture a new active skincare ingredient based on SkinBiotix™ technology and investigate specific cosmetic ingredient applications to target.
- First commercial deal around SkinBioTherapeutics’ SkinBiotix™ technology.
- Croda is an international speciality chemical company supplying some of the world’s biggest brands.
UK skin health company, SkinBioTherapeutics, has signed a commercial agreement with FTSE 100 company Croda International for the design and manufacture of a new active cosmetic skincare ingredient based on its pioneering SkinBiotix™ skin microbiome technology.
Powered by the discoveries about lysates and the skin microbiome made at the University of Manchester by Professor Cath O’Neill and Professor Andrew McBain, SkinBioTherapeutics is developing a range of scientifically-validated treatments derived from probiotic bacteria. SkinBioTherapeutics’ patented skin microbiome technology, SkinBiotix®, applies lysates derived from probiotic bacteria to the skin, and has been shown to improve the barrier effect of skin models, protect skin models from infection and repair skin models.
Under the terms of the agreement, SkinBioTherapeutics’ proprietary SkinBiotix™ platform will be paired with Croda’s expertise in the development and commercialisation of unique, sustainable, cosmetic ingredients, focusing specifically on the growing skincare actives market. Sederma, part of Croda International, is a specialist in bioactive ingredients for the cosmetic industry, and will be responsible for the development, manufacturing and commercialisation of the SkinBiotix™ technology. As design and build of the active ingredient is carried out there will be concurrent testing in focussed application areas which will be detailed in further, additional agreements.
Any licensed products resulting from this agreement will be sold to Croda’s global portfolio of Personal Care customers. Sales and distribution rights are for the cosmetic sector alone, leaving SkinBioTherapeutics to focus on further applications of its technology in other sectors.
Arnaud Fournial, Managing Director of Sederma, said: “The SkinBiotix™ technology has a solid scientific foundation which attracted us in the first place. We believe the technology has the potential to become an essential and significant component of cosmetic products within the rapidly emerging skin microbiome market. We look forward to a fully collaborative partnership with the SkinBioTherapeutics team and to seeing SkinBiotix™ being embraced by our global partners as a key ingredient across a variety of products to protect and rejuvenate skin.”
Stuart Ashman, CEO of SkinBioTherapeutics, said: “We are delighted to have partnered with a world-leading company such as Croda and to able to utilise the expertise within Sederma. This partnership brings together our innovation in the microbiome space and Sederma’s track record of developing world-class cosmetic ingredients. The strong scientific foundation for our technology, and the pioneering research conducted by our CSO Dr Cath O’Neill to date, has put us in a very strong position to develop a cosmetic ingredient with the potential to really exploit the full potential of the skin microbiome.”
- Ends –
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin health. The Company’s proprietary platform technology, SkinBiotix®, is based upon discoveries made by Dr. Catherine O’Neill and Professor Andrew McBain.
The Company has demonstrated, through scientific testing, that the SkinBiotix® platform can improve the barrier effect of skin models, protect from infection and repair wounds. Proof of principle studies have also shown that the SkinBiotix® platform has beneficial attributes applicable to each of these areas. The technology achieved positive results in clinical studies in human volunteers in early 2019.
The Company listed on AIM in April 2017 and is based in Manchester, UK. For more information, visit: www.skinbiotherapeutics.com.
About Croda International plc
Established in 1925, Croda is the name behind high performance ingredients and technologies in some of the world’s biggest and most successful brands: creating, making and selling speciality chemicals that are relied on by industries and consumers everywhere.
They have a network of over 4,500 passionate and committed employees, working together as one global team across manufacturing sites and offices in 38 countries. Croda is a FTSE100 company with a flexible structure that allows them to focus on developing and delivering innovative, sustainable ingredients that their customers can build on in: Personal Care, Health Care, Crop Care, Smart Materials, Energy Technologies, Home Care and Water and Industrial Specialities.
For more information, please visit: www.croda.com
About Sederma
Founded in 1964, Sederma became a member of the Croda International Group in 1997. Sederma is dedicated to the development of active ingredients and in the creation of innovative concepts for cosmetics, based on the mastery of biotechnology, plant cell culture, fine chemistry and vegetal extraction. Sederma has developed a unique range of actives with substantiated efficacy for facial skin care, body care, sun care, hair care and men’s care.
Sederma is actively committed to minimise its social and environmental impacts on its stakeholders without compromising innovation, quality and safety in line with Croda CSR strategy. All efforts have been put for many years to set-up a holistic view of doing Business by placing equal emphasis on the Planet, People and profit.
For more information, please visit: www.crodapersonalcare.com
